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Dyspnoea is the most common symptom associated with poor quality of life in patients
affected by Chronic Obstructive Pulmonary Disease (COPD). While COPD severity is commonly
staged by lung function, the Medical Research Council (MRC) dyspnoea scale has been proposed
as a more clinically meaningful method of quantifying disease severity in COPD. We wished to
assess whether this scale might also be useful during telephone surveys as a simple surrogate
marker of perceived health status in elderly patients with COPD.
We conducted a comprehensive health status assessment by telephone survey of 200 elderly
patients who had a physician diagnosis of COPD. The telephone survey contained 71 items and
explored such domains as educational level, financial status, living arrangements and social
contacts, co-morbid illness, and the severity and the impact of COPD on health status. Patients
were categorized according to the reported MRC score: mild dyspnoea (MRC scale of 1),
moderate dyspnoea (MRC scale of 2 and 3), or severe dyspnoea (MRC of 4 and 5). Deterioration
in most of the recorded indicators of health status correlated with an increasingly severe MRC
score. This was most evident for instrumental activities of daily living (IADL), perceived health
and emotional status, pain-related limitations, limitations in social life, hospital admissions in
preceding year and prevalence of most co-morbidities.
The MRC dyspnoea scale is a reliable index of disease severity and health status in elderly
COPD patients which should prove useful for remote monitoring of COPD and for rating health
status for epidemiological purposes.
ª 2010 Elsevier Ltd. All rights reserved.o di Geriatria, Universita` Campus Bio-medico, via Alvaro del Portillo 21, 00128, Rome, Italy. Tel.: þ39
pus.it (L. Paladini).
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COPD is a major cause of impaired health status, disability
and mortality,1 and most current clinical practice guide-
lines define the severity of COPD in terms of the level of
forced expiratory volume in 1 s (FEV1).
2,3 However, because
FEV1 correlates only weakly with patient-centred outcomes
such as exercise capacity, activities of daily living (ADL) and
quality of life in COPD,4e6 it is generally accepted that
additional tools are required to adequately assess the
impact that this disease has on patients7,8 and the
measurement of health status (also referred to as health-
related quality of life) has become a commonly measured
outcome in COPD clinical trials,9 While generic question-
naires assessing health status, such as the SF-36, may have
some use in COPD,10 most recent clinical trials have used
COPD-specific tools such as the St. George’s Respiratory
Questionnaire (SGRQ), or the Chronic Respiratory Ques-
tionnare (CRQ).11,12 Although these health status ques-
tionnaires provide well-validated measurements of
disability and handicap due to COPD, they are lengthy and
have a degree of complexity that makes them too time-
consuming for routine clinical use. A short form CRQ has
recently been validated,13 but like the original CRQ, it is
personalized to the individual patient and so not particu-
larly suitable for comparison amongst patients. Thus there
is a need for a simpler, standardised method for scoring
disability in COPD.
Dyspnoea is the most disabling symptom of COPD and the
degree of dyspnoea is an important factor in the patient’s
perception of the illness. The Medical Research Council
(MRC) scale14 is a five-point rating scale based on the
patient’s perception of dyspnoea while walking distances
on the level or climbing. This dyspnoea scale is simple to
administer and significantly correlates with other dyspnoea
scales15 and with scores of health status.16 It is also more
responsive than FEV1 in tracking changes in health status in
COPD.17 In a recent primary care survey the MRC scale was
shown to have the best correlation with a new, validated
COPD severity score (COPDSS),18 and it has been used to
stratify patients in pulmonary rehabilitation programs.19
During the last decade, the MRC scale has also been used to
predict mortality20,21 and to assess the efficacy of treat-
ment in patients affected by COPD.22e25 It has been
proposed as a fast and clinically meaningful method of
categorising patients with regard to COPD-related
disability,26 and has been recommended as the preferred
marker of COPD severity over FEV1 in the Canadian Thoracic
Society COPD clinical practice guidelines.27
Among numerous technological advances in medical care,
the use of the telephone for health care management has
increased in scope and application. Indeed, telephone
surveys may be appropriate for many chronic disorders28e32
and may provide useful information on the clinical conse-
quences of COPD.33 The COPDSS was originally developed
from data obtained during a telephone survey of patients
with established COPD.34 Nevertheless it may be criticized
for the absence of objective measurement of disease severity
such as FEV1.
35,36 In this regard, it is interesting to note that
recent investigators have used the MRC to stage COPD
severity in telephone surveys in Canada37 and in America.33The aim of the present study was to assess whether the MRC
dyspnoea scale might also be useful during telephone surveys
as a fast and reliable way of rating perceived health status in
elderly patients with COPD.
Materials and methods
Study population
After giving consent, a sample of 200 Italian home dwelling
COPD patients over 64 years of age underwent a compre-
hensive health status assessment by telephone interview.
Patients were randomly selected from an administrative
database of patients having a spirometrically confirmed
diagnosis of COPD and regularly followed by respiratory
physicians. Thus, the studied sample is representative of
elderly COPD patients receiving specialist care. The survey
was conducted in April 2008. It conformed to guidelines
provided by the Ethical Committee of the Campus Bio-
Medico University.
Survey questionnaire
The telephone survey contained 71 items and took
approximately 40 min to complete. Survey questions were
conceived and written by the investigators and GfK Eurisko
Health Care Department. Interviewers experienced with
telephone and population-based surveys conducted the
telephone interviews from a script to ensure consistency
amongst all interviewers. Because this was the first time
the questionnaire had been used, it was piloted to ensure
that questions and responses were unambiguous to
respondents.
The telephone-based interview was performed to eval-
uate the degree of disability imposed by COPD on the pop-
ulation surveyed. Interviewers first ascertained whether
respondents met study inclusion criteria of having a physi-
cian and spirometrically confirmed diagnosis of COPD, were
64 years of age or older and had a smoking history. Educa-
tional level, financial status, living arrangements and social
contacts were also ascertained. The remainder of the
interview used the questionnaire to explore the impact that
COPD had on the lives of the respondents. Information
requested included: duration of COPD, symptoms, pharma-
cotherapy used, use of supplemental oxygen, experience
with pulmonary rehabilitation, frequency of emergency
room visits and hospitalizations and the presence of co-
morbid illness. Interviewers also probed the impact that
COPD had on patient-centred values including: perceived
health and emotional status, limitations in social life and in
activities of daily living (ADL), and pain-related limitations in
activities of daily living. To evaluate the perceived health
status we used a simple Likert scale with values from 1 (low
quality) to 5 (excellent). Similarly, emotional status was
quantified by asking how long the patient had felt sad during
the past 4 weeks (scale from 1Z never, to 6Z always).
Limitations in social life were measured by a scale from 1
(never) to 5 (always), whereas limitations in activities of
daily living were quantified using a scale from 0 (no limita-
tion) to 2 (1Z partially limited, 2Z totally limited). For
pain-related limitations we used a similar scale ranging from
Table 2 Patient demographics.
The MRC dyspnoea 10290 (no limitations) to 4 (totally limited). Assessment of func-
tional status was done using both the basic ADL and instru-
mental ADL (IADL) scales. Basic ADL are activities allowing
people to live at home with some external help and consist
of items such as having a bath, dressing, going to toilette,
issues with bowel continence, moving from bed to chair,
eating, etc. IADL are activities associated with being inde-
pendent indoors, such as use of telephone, cooking, taking
care of the home, washing clothes, taking medications, etc.
and with outdoor independence, including doing the shop-
ping, going out, managing money, etc. According to this
hierarchy, IADL are usually lost before ADL, but occasionally
selected ADL, e.g. urinary continence, may be lost despite
well preserved IADL.
MRC dyspnoea scale and IADL scale were widely used for
postal and telephone surveys in previous studies, furthermore
ADL scale was formally validated in these contexts.38e43
Subjects were classified according to symptom severity using
the MRC dyspnoea scale based on their responses to questions
about breathlessness posed by the interviewers (Table 1). In
order to simplify analysis, we defined an MRC scale of 1 as
‘‘mild’’ dyspnoea, an MRC scale of 2e3 as ‘‘moderate’’
dyspnoea and an MRC scale of 4e5 as ‘‘severe’’ dyspnoea.
Statistical analysis
Statistical analysis of all variables was conducted using
commercially available software (Statistica ’99 Edition for
Windows). Frequencies or percentages were used to
describe nominal data.
Based on reported MRC scores, we categorized patients
into 3 groups: mild, moderate and severe and then
compared these MRC-based groups with various survey
response items. A chi-square test was employed when
testing for differences between the 3 groups of patients for
nominal data. To assess differences amongst group mean
values, we used analysis of variance (ANOVA) for variables
with a normal distribution, or the KruskaleWallis test for
those variables that were not normally distributed. Post hoc
comparison between groups for continuous variables was
made by the Tukey test.44 Statistical significance for all
analysis was accepted at a level of p< 0.05.Table 1 MRC Scale and Severity Categories.
MRC
Grade
Description MRC Severity
Grouping
1 Breathless with strenuous
exercise
MILD
2 Short of breath when hurrying
on the level or walking up
a slight hill
MODERATE
3 Walks slower than people of
the same age on the level or
stops for breath while walking
at own pace on the level
4 Stops for breath after
walking 100 m
SEVERE
5 Too breathless to leave the
house or breathless when dressingResults
Demographics
Patient demographics are listed in Table 2. Two hundred
patients (146 male, 54 female) with a mean age of
74.4 6.2 years were enrolled in the survey. Ages ranged
from 65 years to over age 80 and were fairly evenly
distributed: 23% aged 65-69 years, 32% aged 70e74 years,
21% aged 75e79 years and 24% aged 80 years or above.
Patients were also evenly distributed geographically with
23% living in the north-west of Italy, 15% in the north-east,
20% in central Italy and 42% in the south and/or the islands.
The majority of patients had at least an elementary school
level of education (80%) and consistent with the advanced
age of respondents, 89% were retired.
Severity and impact of COPD on symptoms
and health status
Classification of patients by MRC score and the mean MRC
scores are shown in Table 3. The majority of patients (62%)
interviewed reported moderate or severe dyspnoea as
defined by MRC groupings. Table 4 shows the average values
for various patient demographics based on MRC severity
groupings. Patients in the three MRC severity groups did not
differ significantly by age, geographic location or smoking
burden as assessed by pack years. Patients with the most
severe COPD by MRC score had less formal education than
patients with mild disease.
Table 5 shows the relationship between MRC dyspnoea
groupings and various disease impact parameters. Most of
the recorded indicators of health status worsened
progressively with MRC severity score. Although there was
no statistically significant correlation of basic ADL scores
and dyspnoea grade, there were significant differences in
IADL amongst all MRC severity scores. Statistically signifi-
cant differences were also found among the 3 MRC severity
scores for perceived health status, emotional status, pain-Population (200 patients)
Age (years) 65e69 23%
70e74 32%
75e79 21%
>80 24%
Geographic location
in Italy
North-West 23%
North-East 15%
Centre 20%
South & Islands 42%
School education No qualification 22%
Elementary school 46%
Lower middle school 18%
Higher middle school 12%
University 2%
Employment status Currently working 1%
Retired 89%
Unemployed 1%
Housewife 9%
Table 3 Distribution of MRC severity scores in population
sampled.
MRC Dyspnoea
Classification
Number of patients
(% total)
Mean MRC
Score
‘‘Mild’’ (MRC 1) 76 (38%) 1
‘‘Moderate’’ (MRC 2e3) 53 (26.5%) 2.3
‘‘Severe’’ (MRC 4e5) 71 (35.5%) 4.5
1030 L. Paladini et al.related limitations and limitations in social life. Patients
with MRC ‘‘severe’’ scores had significantly more hospital
admissions in the preceding year than those with MRC
‘‘mild’’ and ‘‘moderate’’ scores (1.56, 1.07 and 0.43 per
year respectively) and patients with MRC ‘‘moderate’’
scores had more hospitalizations than those with MRC
‘‘mild’’ scores. Patients with MRC ‘‘severe’’ scores also had
more emergency department visits in the preceding year
than patients with MRC scores of ‘‘moderate’’ and ‘‘mild’’
severity, but no differences were seen in the number of
emergency department visits between patients with MRC
‘‘mild’’ versus ‘‘moderate’’ severity scores.
The prevalence of comorbidity was also tracked by MRC
severity score. Fig. 1 demonstrates that co-morbid illnesses
were significantly more prevalent in patients with MRC
‘‘severe’’ scores compared to those with MRC ‘‘mild’’
severity (4.94 versus 2.67). Fig. 2 illustrates prevalence of
individual co-morbidities according to MRC severity score.
There were significant differences amongst patients with
MRC ‘‘mild’, ‘‘moderate’’ and ‘‘severe’’ scores with regard
to the prevalence of heart disease, diabetes, hypertension,
osteoporosis and fractures. The need for long-term oxygen
therapy was also tracked by MRC severity score (10.5%,
41.5%, 59.6% respectively). There were no significant
differences by MRC severity score for use of pulmonary
rehabilitation, duration of COPD, or living arrangements
and social contacts.
Discussion
This study confirms that in an elderly COPD population,
telephone administration of the MRC dyspnoea severityTable 4 Relationship of MRC severity classification to patient d
Mean (SD)
MRC ‘‘Mild’’ (76)
Age (years) 72.7
Smoking burden
(pack years)
30.1 (27)
School Education (years) 7.0a (3.54)
Number of people
living with patient
1.3 (1.08)
Sex 75% Male; 25% Female
Geographic location
North-West 30.30%
North-East 15.80%
Centre 23.70%
South & Islands 30.20%
a pZ 0.02 MRC ‘‘Severe’’ vs. MRC ‘‘Mild’’.score can be used as a simple, robust surrogate marker of
health status, summarizing several important variables
pertaining to mood, personal independence and use of
health care resources. Thus, rating dyspnoea with the MRC
scale convincingly classifies elderly COPD patients accord-
ing to their health status and the burden imposed by the
disease. This makes MRC a very useful tool for epidemio-
logical purposes. However, the lack of information on its
responsiveness when administered through telephone
prevents us form recommending it for the follow up of the
individual patient.
Compared to basic ADLs, the relationship between MRC
and personal independence was more evident for IADLs,
which showed a progressive decline with increasing MRC
scores. This is not surprising, given that IADLs cover a broad
range of individual capabilities which are lost earlier and
more gradually than ADLs.45 Patients experience limitations
in ADLs when their clinical status is dramatically worsened,
which corresponds to an MRC severity threshold of 4. An
MRC severity score 4 thus targets truly disabled individ-
uals highly dependent on external help for activities of
daily living. This finding reflects the true heterogeneity of
health status in COPD population, confirming previous
findings by several investigators.20,21,46e51
The MRC score may be a good surrogate for formal
health status assessment because it is likely not just
a marker of lung dysfunction. It is likely that co-morbidity,
whose burden paralleled MRC severity, contributes to the
MRC severity score and thus to health status. For example,
left heart dysfunction could worsen dyspnoea. Similarly,
thoracic vertebral compression fractures associated with
osteoporosis may worsen dyspnoea by induction of
a restrictive ventilatory deficit, as fracture of a thoracic
vertebral body can decrease the vital capacity by 4e7%.52
Furthermore, osteoporosis might be responsible for pain-
related limitations, which in our patients amounted to
a significant 81% prevalence (15.5% mild, 31.5% moderate,
26.5% severe, 7.5% very severe limitations). Pain is not
among the symptoms usually asked about in COPD patients,
but our data show that it is highly prevalent and disabling.
We also observed that the MRC severity score was
a marker of health care resource needs as expressed byemographics.
MRC ‘‘Moderate’’ (53) MRC ‘‘Severe’’ (71)
74.3 76.4
36.4 (30) 31.5 (29)
6.28 (4.33) 5.4a (3.01)
1.3 (0.76) 1.3 (0.89)
73.6% Male; 26.4% Female 70.4% Male; 29.6% Female
17% 21.10%
17% 12.70%
22.60% 12.70%
43.40% 53.50%
Table 5 Relationship of MRC severity classification to COPD impact.
MRC ‘‘Mild’’
(76)
MRC ‘‘Moderate’’
(53)
MRC ‘‘Severe’’
(71)
Test HSD Tukey (p value)
Mean (SD) Mean (SD) Mean (SD) ‘‘Mild’’ vs
‘‘Moderate’’
‘‘Mild’’ vs
‘‘Severe’’
‘‘Moderate’’ vs
‘‘Severe’’
ADL score 5.66 (0,81) 5.23 (0,95) 3.53 (1,79) n.s.b <0.001 <0.001
IADL score 7.49 (1,26) 5.83 (2,34) 3.46 (2,12) <0.001 <0.001 <0.001
Perceived health status 2.71 (0,69) 1.98 (0,8) 1.48 (0,67) <0.001 <0.001 <0.001
Emotional status 2.22 (0,68) 2.62 (0,76) 3.03 (1) 0.0197 <0.001 0.0194
Pain-related limitation 1.00 (1,02) 2.04 (1,04) 2.76 (0,8) <0.001 <0.001 <0.001
Limitation in social life 1.97 (0,83) 2.94 (0,89) 3.39 (0,82) <0.001 <0.001 0.0089
Limitation moderate
physical activity
0.67 (0,66) 1.26 (0,59) 1.73 (0,5) <0.001 <0.001 <0.001
Limitation stairs 0.67 (0,66) 1.30 (0,61) 1.72 (0,51) <0.001 <0.001 <0.001
Hospital admissions
last year
0.43 (0,66) 1.07 (1,28) 1.56 (1,36) 0.004 <0.001 0.0437
ED visits last year 0.18 (0,58) 0.55 (1.05) 1.21 (1,44) n.s.b <0.001 0.0019
Number of co-morbid
illnesses
2.67 (1,69) 3.38 (2) 4.94 (2,15) n.s.b <0.001 <0.001
% patients on
long-term oxygen
10.50% 41.50% 59.20% <0.001a <0.00a <0.001a
a chi-square test.
b statistically non-significant.
The MRC dyspnoea 1031hospital and emergency department admissions in the
preceding year and by the use of supplementary oxygen. This
observation deserves consideration because although respi-
ratory symptoms are important, non-respiratory problems
are known to be main determinants of the need to access
health care resources. Non-respiratory causes trigger up to
60% of admission of COPD patients,53e57 and the cost of
hospital care is directly related to the number of co-morbid
conditions.58e61 Thus, dyspnoea as quantified by the MRC
score can function as a marker of the need to access health
care resources, perhaps because as we have shown, it is
a robust indicator of overall health status in COPD. It is of
interest that the fraction of patients undergoing rehabilita-
tion did not increase for increasingMRC score (11.8% patients
with mild dyspnoea, 22.6% with moderate and 15.5% with
severe dyspnoea) This may reflect the availability or lack of
availability of pulmonary rehabilitation in the populationFigure 1 Number of co-morbid illnessurveyed, as well as physician prescribing practices. Which-
ever is the explanation, it is disturbing that about half
patients regularly cared by respiratory physicians never
underwent a non pharmacological intervention of proved
efficacy even in very severe COPD.62e67
The availability of an easy to use telephone-based
assessment instrument that reflects health status is of
special interest for both clinical and epidemiological
purposes. The MRC scale can be used for quick assessment or
for large surveys. In the latter instance, its measurement
properties could permit stratification of patients according
to COPD-related health status impairment. It also is likely,
yet unproved, that MRC scale qualifies as a telephonemarker
of individual response to therapeutic interventions, similar
to the way it has been used in traditional ambulatory-based
studies.21e25,62 More important, telephone-based assess-
ments of disability are of special interest in patientses related to MRC severity score.
Figure 2 Prevalence of specific co-morbidities by MRC dyspnoea group.
1032 L. Paladini et al.populations experiencing severe limitations in mobility. In
our series 16% of the total population enrolled were not able
to leave their homes due to breathlessness or other limita-
tions, and in other studies on elderly COPD populations, the
prevalence of home confined subjects ranged between 11.9%
and 34%.21,35 Thus, a consistent proportion of patients would
be and actually is excluded from both clinical trials and
epidemiological studies because they are confined at home,
The MRC-based telephone surveys allows to take into
consideration these people at least for epidemiological
purposes or clinical screening studies.
Limitations of this study deserve consideration. First,
patients were representative of a COPD population under
regular specialist care and not of the general COPD
population. Furthermore, we had no access to lung func-
tion data and thus, were not able to correlate our findings
with FEV1-based disease severity assessment. Second,
females were underrepresented (73% male, 27% female),
which makes our results more tailored to an elderly male
COPD population. Thirdly, some components of this ques-
tionnaire had not been previously validated for telephone
survey.
Notwithstanding these limitations, the results from our
survey are similar to those obtained from two recent tele-
phone surveys of COPD patients in Canada37 and Amer-
ica33with regard to the relationship between MRC score and
health status impairment Both of these surveys also relied
upon physician diagnosis of COPD and did not have access to
FEV1 data. The Canadian and American surveys did not
restrict the age of respondents to the elderly as we did in
our survey (mean age 74.4 years), but both assessed COPD
severity using the MRC dyspnoea scale. Furthermore, using
the MRC dyspnoea groupings used in our study, the distri-
butions of ‘‘mild’’, ‘‘moderate’’ and ‘‘severe’’ dyspnoea
grades were 26%, 44%, 26% in the Canadian survey37 and
12%, 50%, 36% in the American study33 vs. 38%, 26.5% and
35.5% in our sample. Thus, the important analogies in the
MRC-health status relationship among different COPD pop-
ulations supports the interpretation of COPD as a condition
with a distinctive impact on health status and that of MRC
as a reliable surrogate health status index.
In conclusion, this study shows that the MRC dyspnoea
severity score can also function as a simple surrogate forhealth status and multidimensional assessment. On the
basis of our data, an MRC score> 3 would mark a severely
impaired health status. It is highly suitable for telephone
surveys of COPD patients for epidemiological purposes.
However, our study explored only the classification prop-
erties of the MRC score in an elderly population. Further
research is needed to assess both responsiveness and pre-
dictivity of the telephone-recorded MRC score with regard
to other patient-centred outcomes in COPD patients of all
ages. Clarifying these properties will allow verify to which
extent MRC can be effectively administered through tele-
phone for clinical purposes.
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